广西医科大学学报2025，Vol.42Issue(2)：277-288,12.DOI:10.16190/j.cnki.45-1211/r.2025.02.016
以多柔比星脂质体和表柔比星为基础的乳腺癌患者治疗效果及副作用的meta分析
The efficacy and side effects of liposomal doxorubicin-based therapy and epirubicin-based therapy for breast cancer patients:a meta-analysis
摘要
Abstract
Objective:To conduct a meta-analysis to explore the specific efficacy and side effects of liposomal doxorubicin(LD)and epirubicin(E)-based therapies in breast cancer patients.Methods:We searched 6 databases including PubMed,Embase,CNKI,Wanfang Data,Web of Science,and the Cochrane Library,and adopted retro-spective studies and randomized clinical trials(RCTs)to compare the efficacy and side effects during LD and E-based therapies.Cochrane criteria were followed,and the RevMan 5.3 software was used to analyze the patho-logical complete response rate,as well as the side effects of the trials such as cardiotoxicity,immunotoxicity,he-matotoxicity and neurotoxicity.The odds ratios(OR)and 95%confidence intervals(95%CI)were used to pres-ent the results.Results:In total,we analyzed the results from 3,597 patients in 5 RCTs and 16 retrospective stud-ies.The meta-analysis results showed that the LD-based therapy had better performance than the E-based therapy in pathological complete response rate(OR=1.31),incidence of cardiotoxic events(OR=0.40)and incidence of he-matotoxic events(OR=0.59)(P＜0.05).However,LD-based therapy showed significantly higher immunotoxicity(OR=2.52)and neurotoxicity(OR=0.59)(P＜0.05).Conclusion:Compared with E-based therapy,LD-based therapy is generally more suitable for breast cancer patients.However,for patients with a burden of immune sys-tem and nervous system diseases or other related contraindications,careful selection should be made.关键词
多柔比星脂质体/表柔比星/乳腺癌/疗效/副作用/Meta分析Key words
liposome doxorubicin/epirubicin/breast cancer/efficacy/side effects/meta-analysis分类
临床医学引用本文复制引用
邓浪,熊大艳,田珈硕,丁金锋,唐四元,刘伟..以多柔比星脂质体和表柔比星为基础的乳腺癌患者治疗效果及副作用的meta分析[J].广西医科大学学报,2025,42(2):277-288,12.基金项目
新疆医科大学科研创新团队项目资助(No.XYD2024C06) （No.XYD2024C06）
